Osaka University

Shionogi Company Limited

Chugai Seiyaku Kabushiki Kaisha

Shimon Sakaguchi

Tomoyuki Igawa

Atsushi Tanaka

Tetsuya Yoshida

Norio Nonomura

Hisashi Wada

Naganari Ohkura

Atsunari Kawashima

Hiroyoshi Nishikawa

Yujiro Kidani

Mitsunobu Matsumoto

Takayuki Kanazawa

Satomi Shinonome

Kanji Hojo

Yutaka Matsuda

Yuji Hori

Shun Shimizu

Takahiro Ishiguro

Hiroki Kawauchi

Kanako Tatsumi

Masaki Kamimura

Hiroki Hayashi

Yasunori Komori

Hitoshi Katada

Hiroaki Susumu

The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Pc region and methods of producing and using the polypeptides.

Anti-CTLA-4 antibody and use thereof

The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.

Method of treating cancer with an anti-CCR8 that binds tumor infiltrating cells

It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.

T cell-redirected antigen-binding molecule for cells having immunosuppression function

An object of the present invention is to provide an immunopotentiating agent for reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity. Imatinib and/or a salt thereof has the action of reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity, and can be used as an active ingredient for the immunopotentiating agent.

Immunopotentiator potentiating tumor immunity or infection immunity

Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8

Growing community of inventors

Osaka, Japan

Shimon Sakaguchi